Insmed (NASDAQ:INSM) Bolsa

INSMED INC

Insmed

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Jim Cramer- AI Is Bigger Than Rate Cuts

Long Ideas

News

Markets

Media

Trading Ideas

INSM

OUST

PAAS

PSNL

TSLA

Cramer evita acciones especulativas como Tempus AI e Insmed y prefiere Pan American Silver por su rentabilidad constante.

Jim Cramer advierte sobre Tempus AI e Insmed y apuesta por Pan American Silver

Insmed Inc

Wells Fargo analyst Tiago Fauth maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Overweight and raises the price target from $119 to $130.

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $130

Morgan Stanley analyst Matthew Harrison maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Overweight and raises the price target from $102 to $108.

Morgan Stanley Maintains Overweight on Insmed, Raises Price Target to $108

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 2.94% on an annualized basis producing an average annual return of 14.32%. Currently, Insmed has a market capitalization of $18.67 billion. 
Buying $100 In INSM: If an investor had bought $100 of INSM stock 10 years ago, it would be worth $388.37 today based on a price of $98.28 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752277512_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

In a market increasingly defined by volatility and uncertainty, investors are grappling with a mix of opportunities and risks. The recent turmoil in the tech sector, particularly among companies heavily reliant <a href="https://www.benzinga.com/topic/artificial-intelligence">on artificial intelligence</a>, has raised questions about sustainability and profitability.
On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) is another company that's just losing money &#8220;hand over fist,&#8221; so he recommended not <a href="https://www.benzinga.com/general/biotech/25/07/46331040/personalis-and-tempus-extend-partnership-through-2029-add-colorectal-cancer-to-mrd-test-deal-cove">going there</a>.
According to recent news, Personalis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) announced on Wednesday an expansion and extension of its strategic collaboration with Tempus AI, adding a new indication, colorectal cancer, to the existing, exclusive commercialization agreement.
When asked about First Majestic Silver Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AG#NYSE">AG</a>), he said, &#8220;I like silver. First Majestic, not familiar with. The one that I've always recommended is Pan American (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAAS#NASDAQ">PAAS</a>) because it's been profitable for a very long time.&#8221;
First Majestic Silver, on Wednesday, issued second-quarter production numbers and raised its FY25 silver and gold outlook.
Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) is &#8220;very speculative,&#8221; Cramer said. &#8220;It has lost a huge amount of money, so it's very hard for me to get a handle on it.&#8221;
According to recent news, Insmed announced topline results from its randomized, double-blind, placebo-controlled Phase 2b study evaluating the efficacy and safety of treprostinil palmitate inhalation powder on Thursday. The study met its primary endpoint and all secondary efficacy endpoints.
&#8220;I don't think that there's anything investible in, honestly, in autonomous, other than Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>),&#8221; Cramer said when asked about Ouster, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NASDAQ">OUST</a>). &#8220;I'm going to say no, too speculative.&#8221;
Supporting his view, WestPark Capital analyst Casey Ryan, on June 12, downgraded Ouster from Buy to Hold.
Price Action:
<ul class="wp-block-list">
<li>Tempus AI shares fell 0.2% to settle at $58.41 on Wednesday.</li>
<li>First Majestic Silver shares gained 5.5% to close at $8.43.</li>
<li>Ouster shares gained 6.4% to settle at $24.63 on Wednesday.</li>
<li>Insmed shares rose 0.3% to close at $96.47.</li>
</ul>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46316741/top-3-risk-off-stocks-that-may-rocket-higher-in-q3">Top 3 Risk Off Stocks That May Rocket Higher In Q3</a></li>
</ul>
Image created using photos from Shutterstock.

Cramer Says Tesla Dominates While Ouster Is 'Too Speculative'

In the latest quarter, 12 analysts provided ratings for Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Insmed, presenting an average target of $109.0, a high estimate of $120.00, and a low estimate of $90.00. This current average has increased by 12.48% from the previous average price target of $96.91. 
<img src="https://www.benzinga.com/files/images/story/2025/1752004868_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Insmed's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$111.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Andrea Tan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$106.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$102.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Jason Zemansky</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$109.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Tiago Fauth</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$119.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$120.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Joseph Schwartz</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Kelly Shi</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$109.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Insmed. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insmed compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Insmed's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Insmed's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/INSM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Insmed analyst ratings.</a>
<h2>Unveiling the Story Behind Insmed</h2>
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
<h3>Key Indicators: Insmed's Financial Health</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Insmed's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 22.94%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -276.42%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Insmed's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -133.45%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -13.41%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Insmed's debt-to-equity ratio surpasses industry norms, standing at 11.53. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Insmed Through 12 Analysts

JP Morgan analyst Jessica Fye maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Overweight and raises the price target from $90 to $111.

JP Morgan Maintains Overweight on Insmed, Raises Price Target to $111

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 3.38% on an annualized basis producing an average annual return of 14.93%. Currently, Insmed has a market capitalization of $18.66 billion. 
Buying $100 In INSM: If an investor had bought $100 of INSM stock 10 years ago, it would be worth $403.45 today based on a price of $98.24 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751499910_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today

Insmed's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NYSE">INSM</a>) short percent of float has risen 5.99% since its last report. The company recently reported that it has 17.46 million shares sold short, which is 10.8% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.27 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Insmed Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750341623_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Insmed has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Insmed's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Insmed's peer group average for short interest as a percentage of float is 6.63%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What Does the Market Think About Insmed?

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol class="wp-block-list">
<li>Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) stock jumped 34.11% last week after announcing <a href="https://www.benzinga.com//node/45856129">positive topline results</a> from a Phase 2b study on treprostinil palmitil inhalation powder, which met all primary and secondary endpoints. Multiple firms also raised their <a href="https://www.benzinga.com/quote/insm/analyst-ratings">price forecasts on the stock</a>.</li>
<li>Circle Star Energy Corp.'s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) stock jumped 24.01% last week following continued market strength <a href="https://www.benzinga.com//node/45874849">following its IPO launch</a>.</li>
<li>Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) stock jumped 23.68% last week after the company reported better-than-expected <a href="https://www.benzinga.com//node/45893773">Q4 financials</a> and issued upbeat guidance. Several analysts raised <a href="https://www.benzinga.com/quote/ORCL/analyst-ratings">their price forecasts</a>.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) stock jumped 23.02% last week after the company announced a settlement enabling access to 45 MHz of spectrum in North America and that it is set to join the Russell 1000 Index on June 27.</li>
<li>SailPoint Technologies Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAIL#NYSE">SAIL</a>) stock jumped 18.56% last week after the company posted strong <a href="https://www.benzinga.com//node/45882090">first-quarter EPS</a>, issued bullish second-quarter and fiscal year 2026 guidance, and received <a href="https://www.benzinga.com/quote/SAIL/analyst-ratings">multiple analyst upgrades</a>.</li>
<li>Vonage Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VG#NASDAQ">VG</a>) stock jumped 15.90% last week after UBS downgraded it to Neutral but raised its <a href="https://www.benzinga.com/quote/VG/analyst-ratings">price forecast to $18</a>.</li>
<li>Telefonica Servicios Moviles S.A. ADS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) stock jumped 14.84% last week after Cathie Wood's ARK Invest <a href="https://www.benzinga.com//node/45831272">purchased large quantities of stock</a> in its (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#NYSE">ARKG</a>) and (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) ETFs.</li>
<li>Casey's General Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) stock jumped 13.99% last week on <a href="https://www.benzinga.com//node/45849848">strong Q4 results</a> and a dividend hike, <a href="https://www.benzinga.com/quote/CASY/analyst-ratings">prompting analyst upgrades</a>.</li>
<li>Equinor ASA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQNR#NYSE">EQNR</a>) stock jumped 13.17% last week as energy sector stocks rallied on Middle East tensions that spiked oil prices.</li>
<li>Halliburton Company's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) stock jumped 13.01% last week, fueled by rising oil prices and geopolitical conflict in the Middle East.</li>
</ol>
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45940506/applovin-chewy-and-carvana-are-among-top-11-large-cap-losers-last-week-june-9-13-are-the-others-in-your-portfolio">AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio?</a></li>
</ul>
Photo by Sundry Photography via Shutterstock

Large Cap

Movers

ARKG

ARKK

ASTS

CASY

CRCL

EQNR

ORCL

SAIL

Oracle, AST SpaceMobile And Halliburton Are Among Top 10 Large Cap Gainers Last Week (June 9-13): Are The Others In Your Portfolio?

Reported Earlier, Insmed Prices $750M Public Offering Of 7,812,500 Shares At $96 Each

Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) has outperformed the market over the past 10 years by 4.43% on an annualized basis producing an average annual return of 15.51%. Currently, Insmed has a market capitalization of $17.70 billion. 
Buying $100 In INSM: If an investor had bought $100 of INSM stock 10 years ago, it would be worth $425.63 today based on a price of $97.20 for INSM at the time of writing.
<h3>Insmed's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749684615_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Today

Offerings

Insmed Announces Proposed $650M Public Offering

Goldman Sachs analyst Andrea Tan maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $100 to $112.

Goldman Sachs Maintains Buy on Insmed, Raises Price Target to $112

Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) on Tuesday released topline results from its Phase&nbsp;2b&nbsp;study of treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">pulmonary arterial hypertension</a>.
The study met its primary endpoint and all secondary efficacy endpoints. For the primary endpoint, the placebo-adjusted reduction from baseline in pulmonary vascular resistance (PVR) was 35%, with a Least Squares (LS)&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45856129/insmed-announces-positive-topline-results-from-phase-2b-study-of-treprostinil-palmitil-inhalation-" rel="noreferrer noopener">mean ratio of 0.65</a>.
The placebo-adjusted improvement in six-minute walk distance (6MWD) was 35.5 meters for the secondary efficacy endpoints.
Also Read: <a href="https://www.benzinga.com/general/biotech/25/02/43957368/lung-disease-focused-insmed-is-an-attractive-midcap-biotech-analyst-says" target="_blank" rel="noreferrer noopener">Lung Disease-Focused Insmed &#8216;Is An Attractive Midcap Biotech,&#8217; Analyst Says</a>
The placebo-adjusted reduction from baseline in N-terminal pro-b-type natriuretic peptide (NT-proBNP) concentrations, a biomarker for cardiac stress, was 60%, with an LS mean ratio of 0.40.
These results demonstrate the durability of TPIP&#8217;s therapeutic effect as a once-daily therapy based on efficacy evaluated approximately 24 hours after administering therapy.
Insmed will engage with the U.S. Food and Drug Administration (FDA) regarding the Phase 3 trial design for PAH.
Insmed plans to initiate a Phase 3 trial in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) before the end of 2025 and a Phase 3 trial in patients with PAH in early 2026.
Once-daily TPIP therapy was well tolerated in the study.
<h2 class="wp-block-heading">What Analysts Are Saying</h2>
Bank of America Securities (BofA) said TPIP data &#8216;exceeded even our bullish outlook.&#8217;
Analyst Jason Zemansky sees &#8220;clear potential for TPIP to become foundational in PAH/ PH-ILD, given the strength of the data and treprostinil&#8217;s well-established role in the paradigm.&#8221;
BofA analyst says that overall, the data looks strong, and there&#8217;s little to criticize. TPIP seems to have a top-tier profile, especially in how it&#8217;s administered. Plus, there&#8217;s good reason to think its effectiveness will improve with higher doses, and safety concerns may decrease with longer dose adjustments.
On Tuesday, BofA increased the price forecast from $94 to $109, <a href="https://www.benzinga.com/quote/INSM/analyst-ratings" target="_blank" rel="noreferrer noopener">reiterating its Buy rating</a>.
BofA still sees several short-term factors that could drive shares higher, but these aren&#8217;t fully reflected in the current price. One is the upcoming FDA decision on brensocatib, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43843781/insmed-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-business-update" rel="noreferrer noopener">expected by August 12</a>.
Although there are good reasons to be optimistic, investor skepticism remains around management&#8217;s ambitious goal of over $5 billion in peak sales. 
Meaningful insights into the launch likely won&#8217;t come until around the first quarter of 2026. However, early feedback from doctors and insurers in the second half of 2025 could help ease some doubts.
HC Wainwright maintained a Buy rating on Insmed and has raised the price forecast from $90 to $120.
Wells Fargo maintained an Overweight rating on Insmed and has raised the price forecast from $107 to $119.
Morgan Stanley maintained an Overweight rating on Insmed and has raised the price forecast from $90 to $102.
RBC Capital maintained an Outperform rating on Insmed and has raised the price forecast from $99 to $106.
Mizuho maintained an Outperform rating on Insmed and has raised the price forecast from $96 to $110.
Price Action: INSM stock is trading higher by 7.04% to $97.33 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/health-care/25/06/45778064/newly-listed-sionna-therapeutics-touts-positive-data-from-lung-disease-candidate-in-healthy-volunteer-trial" target="_blank" rel="noreferrer noopener">Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Biotech

Health Care

General

Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast

Mizuho analyst Graig Suvannavejh maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Outperform and raises the price target from $96 to $110.

Mizuho Maintains Outperform on Insmed, Raises Price Target to $110

RBC Capital analyst Leonid Timashev maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Outperform and raises the price target from $99 to $106.

RBC Capital Maintains Outperform on Insmed, Raises Price Target to $106

WIIM

Insmed shares are trading higher after the multiple firms raised their respective price targets on the stock.

Morgan Stanley analyst Matthew Harrison maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Overweight and raises the price target from $90 to $102.

Morgan Stanley Maintains Overweight on Insmed, Raises Price Target to $102

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham raised Lumentum Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) price target from $100 to $105. Needham analyst Ryan Koontz maintained a Buy rating. Lumentum shares closed at $81.96 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/lite/analyst-ratings">view this stock</a>.</li>
<li>Telsey Advisory Group cut the price target for Academy Sports and Outdoors, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) from $60 to $58. Telsey Advisory Group analyst Cristina Fernandez maintained an Outperform rating. Academy Sports and Outdoors shares closed at $44.60 on Tuesday. See how other analysts view <a href="https://www.benzinga.com/quote/aso/analyst-ratings">this stock</a>.</li>
<li>HC Wainwright &amp; Co. raised Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) price target from $90 to $120. HC Wainwright &amp; Co. analyst Andrew Fein maintained a Buy rating. Insmed shares closed at $90.93 on Tuesday. <a href="https://www.benzinga.com/quote/insm/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity raised the price target for Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) from $87 to $99. Canaccord Genuity analyst Kyle Mikson maintained a Hold rating. Illumina shares closed at $87.98 on Tuesday. <a href="https://www.benzinga.com/quote/ilmn/analyst-ratings">See how other analysts view this stock.</a></li>
<li>BTIG slashed the price target for GitLab Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) from $86 to $67. BTIG analyst Gary Powell maintained a Buy rating. GitLab shares closed at $48.51 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/gtlb/analyst-ratings">view this stock</a>.</li>
<li>Benchmark raised TAT Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TATT#NASDAQ">TATT</a>) price target from $35 to $36. Benchmark analyst Josh Sullivan maintained a Buy rating. TAT Technologies shares settled at $26.40 on Tuesday. <a href="https://www.benzinga.com/quote/tatt/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo raised Marathon Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) price target from $180 to $182. Wells Fargo analyst Roger Read maintained an Overweight rating. Marathon Petroleum shares closed at $162.64 on Tuesday. <a href="https://www.benzinga.com/quote/mpc/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo cut Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>) price target from $149 to $147. Wells Fargo analyst Roger Read maintained an Overweight rating. Phillips 66 shares closed at $118.70 on Tuesday.  <a href="https://www.benzinga.com/quote/psx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BTIG increased the price target for Super Group (SGHC) Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) from $9 to $11. BTIG analyst Clark Lampen maintained a Buy rating. Super Group shares settled at $9.30 on Tuesday. <a href="https://www.benzinga.com/quote/sghc/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS raised Datadog, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) price target from $125 to $140. UBS analyst Karl Keirstead maintained a Buy rating. Datadog shares closed at $119.91 on Tuesday. <a href="https://www.benzinga.com/quote/ddog/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying DDOG stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/DDOG/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="583" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11091354/image-163-1024x583.png" alt="" class="wp-image-946172" style="width:622px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11091354/image-163-1024x583.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11091354/image-163-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11091354/image-163-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/11091354/image-163.png 1112w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45858699/top-2-tech-and-telecom-stocks-you-may-want-to-dump-in-q2">Top 2 Tech And Telecom Stocks You May Want To Dump In Q2</a> </li>
</ul>
Photo via Shutterstock

DDOG

GTLB

ILMN

LITE

SGHC

TATT

Datadog To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday

B of A Securities analyst Jason Zemansky maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and raises the price target from $94 to $109.

B of A Securities Maintains Buy on Insmed, Raises Price Target to $109

Press Releases

Insmed Announces Redemption of all $569.5 Million of Remaining Outstanding 0.75% Convertible Senior Notes Due 2028

Insmed To Present at the BofA Securities 2025 Health Care Conference

Earnings

Insmed Reports First-Quarter 2025 Financial Results and Provides Business Update

Brensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN Study

Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension

Comments

Insmed

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL